SANGUI BIOTECH INTERNATIONAL INC
3, 2001-01-18
NON-OPERATING ESTABLISHMENTS
Previous: TOWER GLOBAL VENTURES CORP, 4, 2001-01-18
Next: SANGUI BIOTECH INTERNATIONAL INC, 3, 2001-01-18





                                                  ------------------------------
                                                           OMB  APPROVAL
                                                  ------------------------------
                                                  OMB Number           3235-0104
                                                  Expires:            12-31-2001
                                                  Estimated  average  burden
                                                  hours  per  response  0.5
                                                  ------------------------------

                     U.S.  SECURITIES  AND  EXCHANGE  COMMISSION
                             Washington,  D.C.  20549

                                     FORM  3

            INITIAL  STATEMENT  OF  BENEFICIAL  OWNERSHIP  OF  SECURITIES

    Filed  pursuant  to  Section  16(a)  of the Securities Exchange Act of 1934,
       Section  17(a)  of  the  Public  Utility  Holding  Company Act of 1935 or
               Section  30(f)  of  the  Investment  Company  Act  of  1940

________________________________________________________________________________
1.   Name  and  Address  of  Reporting  Person*

Borchert, Sieglinde
________________________________________________________________________________
   (Last)                            (First)              (Middle)

Bahnhofstrasse 12

________________________________________________________________________________
                                    (Street)
Witten, Germany   D-58452
________________________________________________________________________________
   (City)                            (State)                (Zip)

________________________________________________________________________________
2.   Date  of  Event  Requiring  Statement  (Month/Day/Year)

December 31, 2000
________________________________________________________________________________
3.   IRS  Identification  Number  of  Reporting Person, if an Entity (Voluntary)

________________________________________________________________________________
4.   Issuer  Name  and  Ticker  or  Trading  Symbol


Sangui Biotech International, Inc. -- SGBI
________________________________________________________________________________
5.   Relationship  of  Reporting  Person  to  Issuer
     (Check  all  applicable)

     [ ]  Director                                [_]  10%  Owner
     [X]  Officer  (give  title  below)           [_]  Other  (specify  below)

Chief Operating Officer
________________________________________________________________________________
6.   If  Amendment,  Date  of  Original  (Month/Day/Year)

________________________________________________________________________________
7.   Individual  or  Joint/Group  Filing  (Check  applicable  line)

     [x]  Form  Filed  by  1  Reporting  Person

     [_]  Form  Filed  by  More  than  1  Reporting  Person

<PAGE>

================================================================================
             Table  I  --  Non-Derivative  Securities  Beneficially  Owned
================================================================================
<TABLE>
<CAPTION>

                                                          3.  Ownership  Form:
                           2.  Amount  of  Securities         Direct  (D)  or
1.  Title  of  Security        Beneficially  Owned            Indirect  (I)       4.  Nature  of  Indirect  Beneficial  Ownership
    (Instr.  4)                    (Instr.  4)                (Instr.  5)             (Instr.  4)

<S>                            <C>                            <C>                     <C>
     Common  Stock            1,000                            D                       N/A
-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------


</TABLE>


Reminder:  Report  on  a separate line for each class of securities beneficially
          owned  directly  or  indirectly.


                                                                          (Over)
                                                                 SEC 1473 (3-99)


<PAGE>

FORM  3  (continued)

              Table  II  --  Derivative  Securities  Beneficially  Owned
         (e.g.,  puts,  calls,  warrants,  options,  convertible  securities)

================================================================================

<TABLE>
<CAPTION>
                                                                                                        5. Owner-
                                                    3. Title and Amount of Securities                      ship
                                                       Underlying Derivative Security                      Form of
                         2. Date Exercisable           (Instr. 4)                                          Derivative
                            and Expiration Date     ---------------------------------    4. Conver-        Security:
                            (Month/Day/Year)                               Amount           sion or        Direct      6. Nature of
                         ----------------------                            or               Exercise       (D) or         Indirect
                         Date       Expira-                                Number           Price of       Indirect      Beneficial
1. Title of Derivative   Exer-      tion                                   of               Derivative     (I)            Ownership
   Security (Instr. 4)   cisable    Date            Title                  Shares           Security       (Instr. 5)     (Instr.5)
----------------------------------------------------------------------------------------------------------------------------------
<S>                      <C>        <C>             <C>                    <C>              <C>            <C>            <C>

N/A

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------------------------

</TABLE>

Explanation  of  Responses:




/s/  Sieglinde Borchert                                       December 13, 2000
---------------------------------------------            -----------------------
      **Signature  of  Reporting  Person                             Date

**   Intentional misstatements or omissions of facts constitute Federal Criminal
     Violations.
     See  18  U.S.C.  1001  and  15  U.S.C.  78ff(a).

Note:  File  three  copies  of  this Form, one of which must be manually signed.
       If  space  provided  is  insufficient,  see  Instruction 6 for procedure.


                                                                          Page 2




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission